Propecia is a prescription oral treatment for adult men with androgenetic alopecia, or male pattern hair loss. Its active ingredient lowers scalp DHT and may slow thinning while supporting hair…
Propecia is a prescription oral treatment for adult men with androgenetic alopecia, or male pattern hair loss. Its active ingredient lowers scalp DHT and may slow thinning while supporting hair growth; the regimen for the chosen strength should be confirmed with a healthcare professional before starting.
Propecia is a prescription oral treatment containing finasteride for adult men with androgenetic alopecia, also called male pattern hair loss or male pattern baldness. The condition develops when genetically sensitive hair follicles gradually shrink under the influence of dihydrotestosterone, or DHT.
The chosen strength and regimen should be confirmed with a healthcare professional before starting. Higher finasteride strengths have a different licensed use in prostate disease and should not be substituted for Propecia without a prescriber’s direction. Propecia is intended for men; women and children should not handle crushed or broken tablets.
DHT affects susceptible follicles by shortening the active growth phase and progressively reducing the diameter of new hairs. Fine, short hairs may replace thicker terminal hairs over time. Finasteride targets this hormonal pathway, whereas cosmetic fibres and styling products only alter the appearance of existing hair.
Propecia is a prescription oral treatment containing finasteride 1 mg for adult men with androgenetic alopecia, also called male pattern hair loss or male pattern baldness. Male pattern baldness often begins with recession at the temples, thinning at the crown, or reduced density across the top of the scalp. Individual follicles respond differently, so treatment tends to preserve vulnerable hairs rather than restore every area of established baldness. Earlier treatment usually gives more remaining follicles to protect. The European Medicines Agency describes finasteride 1 mg as a treatment for androgenetic alopecia in men [1].
Propecia contains finasteride, an active ingredient that inhibits 5-alpha-reductase type II and lowers dihydrotestosterone levels in the scalp.
Finasteride inhibits type II 5-alpha reductase, the enzyme that converts testosterone into dihydrotestosterone. Lower DHT levels reduce the hormonal pressure that drives follicle miniaturisation in androgenetic alopecia. The treatment does not remove testosterone from the body and does not act as a general hormone blocker.
The biological sequence is straightforward:
Finasteride works throughout the body, although the desired clinical effect is on scalp follicles. DHT also has roles in male reproductive tissues, which helps explain why sexual adverse effects can occur in some users. The FDA prescribing information describes finasteride’s inhibition of type II 5-alpha reductase and its effect on serum and scalp DHT [2].
A useful practical distinction is that finasteride addresses a hormonal driver of hair loss, while topical minoxidil supports follicle activity through a different pathway. Some clinicians use both approaches when the expected benefit outweighs the added treatment burden.
Treatment is continuous rather than a short course. A reduction in shedding may appear before visible density improves, while noticeable changes commonly require three to six months of daily use. Assessment at 12 months gives a more reliable view of response because hair grows slowly and photographs taken under similar lighting are more useful than daily mirror checks.
The finasteride regimen for the chosen strength should be confirmed with a healthcare professional before starting. The NHS and MHRA describe finasteride as a prescription treatment requiring appropriate clinical assessment before use [3].
Propecia and generic finasteride 1 mg contain the same active substance and use the same pharmacological pathway when supplied in authorised equivalent formulations. The key issue is the active ingredient and strength, not changing between brand presentation and generic presentation without checking that the medicine remains finasteride 1 mg.
Finasteride 5 mg is intended for prostate-related indications such as benign prostatic hyperplasia. It is not the routine male pattern hair-loss strength. Dutasteride inhibits both type I and type II 5-alpha reductase and has a broader DHT-lowering effect, but its use for male pattern hair loss requires a separate clinical decision.
| Treatment category | Main action and route | Typical role |
|---|---|---|
| Finasteride 1 mg | Oral type II 5-alpha-reductase inhibitor | Male pattern hair loss in adult men |
| Minoxidil | Topical or oral follicle-growth treatment, depending on formulation | Hair-density support through a different pathway |
| Dutasteride | Oral inhibitor of type I and type II 5-alpha reductase | Selected cases requiring specialist assessment |
Topical finasteride is a separate preparation, not the same product as oral Propecia. Its formulation, absorption, authorisation, and clinical evidence can differ. It should not be assumed to provide identical exposure or identical safety characteristics.
Minoxidil can sometimes be combined with finasteride because the mechanisms differ. Combination treatment may increase practical complexity, and scalp irritation or unwanted facial hair can occur with topical minoxidil. Dutasteride may produce stronger DHT suppression, but stronger enzyme inhibition does not automatically mean it is the right first treatment.
Oral finasteride treats a hormonal contributor to male pattern hair loss. Minoxidil works through a different biological pathway and is applied to the scalp in topical formulations. A dermatologist may consider one treatment, the other, or both according to the pattern of thinning, medical history, tolerance, and treatment goals.
Finasteride is more convenient for men who prefer once-daily tablets, yet systemic exposure means sexual and psychiatric precautions matter. Minoxidil avoids the same systemic anti-androgen mechanism, but regular scalp application is essential and irritation can limit use. Dutasteride may be considered when response to finasteride is inadequate, although its broader enzyme inhibition calls for careful prescribing.
No treatment can guarantee restoration of a mature hairline. Propecia is more likely to preserve and thicken susceptible follicles than to recreate follicles that have been absent for many years.
Several avoidable errors reduce the chance of a fair treatment assessment:
A temporary change in shedding does not prove that treatment has failed. Hair-cycle variation, illness, stress, weight loss, and scalp disease can also influence shedding, so persistent worsening deserves clinical review.
Propecia is not suitable for everyone. It is not for you if you are:
Pregnant women must not handle crushed or broken Propecia tablets because finasteride can affect development of male external genitalia in a male fetus. Intact tablets have a protective coating, but handling should still follow the medicine’s safety instructions. Men should tell a healthcare professional if their partner is pregnant or may become pregnant.
Finasteride can lower serum prostate-specific antigen, or PSA, by approximately half after sustained use. A doctor interpreting a PSA result needs to know about finasteride because the measured value may otherwise appear lower than expected. This matters when investigating prostate symptoms or assessing prostate-cancer risk.
Tell the prescriber about:
Finasteride is metabolised in the liver, although clinically important interactions are not common. The prescriber should still review medicines that affect liver function or hormonal pathways. Do not combine Propecia with another finasteride product to increase the dose.
Propecia is intended for men; women and children should not handle crushed or broken tablets. Do not use it without medical review if you have unexplained breast changes, depression, suicidal thoughts, fertility concerns, liver disease, or breast symptoms. Do not combine it with another finasteride product to increase the dose.
Clinical trials of finasteride 1 mg reported sexual adverse events slightly more often than placebo. Reduced libido, erectile dysfunction, and ejaculation problems were among the reported reactions. In the first-year trials described in the product information, sexual adverse events occurred in about 3.8% of men taking finasteride and 2.1% taking placebo; individual rates for reduced libido and erectile dysfunction were lower than 2% [4].
Possible adverse effects include:
Many sexual adverse effects resolved during treatment or after discontinuation in clinical studies, although post-marketing reports describe sexual dysfunction that persisted after stopping. The frequency of persistent symptoms cannot be estimated reliably from spontaneous reports. A new sexual symptom deserves a specific discussion with the prescriber rather than silent continuation or abrupt changes to the regimen.
Psychiatric symptoms require prompt attention. The MHRA has reminded patients and prescribers about depression, suicidal thoughts, and other psychiatric reactions associated with finasteride. Any suicidal thoughts require urgent help. New breast lumps, nipple discharge, persistent breast pain, or marked breast enlargement also need medical assessment.
A small but useful detail: reduced ejaculate volume can be noticeable without representing complete loss of fertility. Men being assessed for infertility should report finasteride use because semen parameters and sexual function may be relevant to the clinical picture.
In clinical practice, doctors usually set a 6- to 12-month review point rather than promising a rapid cosmetic change. The first objective is often stabilising hair loss; visible thickening is a separate outcome and may be modest. A prescriber will also ask about sexual function, mood, fertility plans, liver history, and any breast symptoms.
A doctor may recommend baseline photographs, a scalp examination, or referral to dermatology when the pattern is unusual. Sudden patchy loss, scalp inflammation, scarring, or rapid shedding can suggest a diagnosis other than androgenetic alopecia. Finasteride should not delay assessment of those features.
The WHO pharmacovigilance framework treats suspected adverse reactions as clinically relevant even when a symptom is uncommon. Patients give clinicians better information when they report the symptom, its start date, its severity, and whether it changed after a dose adjustment or treatment interruption.
Pregnancy or the possibility of pregnancy rules out handling crushed or broken Propecia tablets because finasteride may harm development of male fetal genitalia. The medicine is also unsuitable for children and women, and it should not be used by anyone with a known finasteride allergy. MHRA safety information reviewed in 2024 also supports careful assessment of psychiatric history before treatment. A prescriber should know about depression, suicidal thoughts, fertility concerns, liver disease, and breast symptoms before issuing the medicine.
Some men notice less shedding within the first few months, while visible density changes commonly take three to six months. The most useful assessment often occurs after approximately 12 months of continuous treatment because hair follicles move through slow growth cycles. The EMA product information from 2024 describes the need for ongoing treatment to maintain the response. Daily mirror checks can exaggerate small changes, so consistent photographs are more informative.
A missed dose should be skipped if the next scheduled dose is approaching; taking two tablets together is not appropriate. Resume the normal once-daily routine at the next planned time. The NHS explained this approach in patient guidance available in 2025, and it avoids unnecessary extra exposure. A single missed tablet is unlikely to produce an immediate visible change in hair, but repeated missed doses can weaken treatment consistency.
Propecia is generally used continuously when it is tolerated and provides worthwhile benefit. Hair loss usually resumes gradually after stopping because the underlying androgenetic process continues. The MHRA and EMA describe finasteride as a treatment requiring ongoing review of benefits and adverse effects in guidance reviewed in 2024. Long-term use should include discussion of sexual symptoms, mood, fertility plans, and PSA interpretation rather than automatic repeat prescribing without review.
Suicidal thoughts, severe depression, facial or throat swelling, breathing difficulty, and a serious allergic reaction require urgent medical attention. A new breast lump, nipple discharge, or persistent breast pain needs prompt medical assessment. The MHRA issued a 2024 reminder about psychiatric and sexual adverse effects associated with finasteride. Troublesome sexual dysfunction should be reported promptly, even if it does not require emergency care.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 5 reviews
I noticed less hair in the shower after about four months. The crown looked fuller by month eight, although the front hairline changed very little.
Norwich Four months 30 Sept 2026The routine was easy because I took it after brushing my teeth. I did not see dramatic regrowth, but the thinning seemed slower. I developed lower libido and stopped after speaking with my doctor.
Wolverhampton Six months 10 Oct 2026I expected a quick change and nearly gave up early. My six-month photographs showed more coverage around the crown. I had no noticeable side effects.
Hull Three months 13 Oct 2026The shedding settled gradually, and I felt the top looked less see-through under office lighting. I had to remember that stopping would remove the benefit over time, so I discussed continuing before renewing treatment.
Glasgow A year 19 Oct 2026My doctor reminded me to mention finasteride before a PSA test. Hair loss was not my only concern, and the PSA discussion was useful because I had assumed the tablet affected only the scalp.
Plymouth Six months 26 Oct 2026
